journal article·2019-01-08Open access

Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies

Eleonora Calzoni, Alessio Cesaretti, Alice Polchi, Alessandro Di Michele, Brunella Tancini, Carla Emiliani

Abstract

Polymer nanoparticles (NPs) represent one of the most innovative non-invasive approaches for drug delivery applications. NPs main objective is to convey the therapeutic molecule be they drugs, proteins, or nucleic acids directly into the target organ or tissue. Many polymers are used for the synthesis of NPs and among the currently most employed materials several biocompatible synthetic polymers, namely polylactic acid (PLA), poly lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG), can be cited. These molecules are made of simple monomers which are naturally present in the body and therefore easily excreted without being toxic. The present review addresses the different approaches that are most commonly adopted to synthetize biocompatible NPs to date, as well as the experimental strategies designed to load them with therapeutic agents. In fact, drugs may be internalized in the NPs or physically dispersed therein. In this paper the various types of biodegradable polymer NPs will be discussed with emphasis on their applications in drug delivery. Close attention will be devoted to the treatment of cancer, where both active and passive targeting is used to enhance efficacy and reduce systemic toxicity, and to diseases affecting the central nervous system, inasmuch as NPs can be modified to target specific cells or cross membrane barriers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Biology and Biotechnology, Biochemistry and Molecular Biology Section, University of Perugia, Via del Giochetto, 06123 Perugia, Italy

Centro di Eccellenza su Materiali Innovativi Nanostrutturati (CEMIN), University of Perugia, Via del Giochetto, 06123 Perugia, Italy

Department of Physics and Geology, University of Perugia, via Pascoli, 06123 Perugia, Italy

References (98)

Show source-provided references
1. Anti-FSHR antibody Fab’fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells10.1158/1538-7445.AM2016-2065 ↗
2. Protein–and Peptide–Drug Conjugates: An Emerging Drug Delivery Technology10.1016/bs.apcsb.2014.11.001 ↗
3. Nanotech approaches to drug delivery and imaging
4. The dawning era of polymer therapeutics10.1038/nrd1088 ↗
5. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
6. Biomedical applications of biodegradable polymers10.1002/polb.22259 ↗
7. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier10.3390/polym3031377 ↗
9. Use of polylactide-co-glycolide-nanoparticles for lysosomal delivery of a therapeutic enzyme in glycogenosis type II fibroblasts10.1166/jnn.2015.9251 ↗
10. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes10.1016/j.ejpb.2006.11.009 ↗
11. Nanoencapsulation techniques for food bioactive components: A review10.1007/s11947-012-0944-0 ↗
12. Polymer nanoparticles: Preparation techniques and size-control parameters10.1016/j.progpolymsci.2011.01.001 ↗
13. Biopolymer-based nanoparticles and microparticles: Fabrication, characterization, and application10.1016/j.cocis.2014.07.002 ↗
14. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells10.1080/02652048.2018.1453560 ↗
15. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation10.1016/j.ijpharm.2017.11.048 ↗
16. Polymer scaffolds for biomaterials applications10.1021/ma901530r ↗
17. Micro and nano-fabrication of biodegradable polymers for drug delivery10.1016/j.addr.2004.05.002 ↗
18. Biodegradable nanoparticles for drug and gene delivery to cells and tissue10.1016/S0169-409X(02)00228-4 ↗
19. Biodegradable nanoparticles for drug delivery and targeting10.1016/S1359-0286(02)00117-1 ↗
20. Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?10.1016/j.addr.2013.08.008 ↗
21. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies10.1021/acs.chemrev.5b00589 ↗
22. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging10.1016/j.nano.2011.05.016 ↗
23. Smart polymers for the controlled delivery of drugs—A concise overview10.1016/j.apsb.2014.02.005 ↗
24. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications10.1016/j.addr.2012.01.020 ↗
25. pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles10.1016/j.jconrel.2009.09.023 ↗
26. Khanal, S., Adhikari, U., Rijal, N.P., Bhattarai, S.R., Sankar, J., and Bhattarai, N. (2016). pH-responsive PLGA nanoparticle for controlled payload delivery of diclofenac sodium. J. Funct. Biomater., 7.10.3390/jfb7030021 ↗
27. Smart polymeric micelles for gene and drug delivery10.1016/j.ddtec.2005.05.007 ↗
28. “SMART” Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical Nanocarriers10.1021/bc060080h ↗
29. Structure and design of polymeric surfactant-based drug delivery systems10.1016/S0168-3659(01)00299-1 ↗
30. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis10.1016/j.bioeng.2006.05.026 ↗
31. Nanomedicine: Developing smarter therapeutic and diagnostic modalities10.1016/j.addr.2006.09.011 ↗
32. 3D printed tablets loaded with polymeric nanocapsules: An innovative approach to produce customized drug delivery systems10.1016/j.ijpharm.2017.05.074 ↗
33. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters10.1016/j.ejpb.2007.08.001 ↗
34. Solid lipid nanoparticles for parenteral drug delivery10.1016/j.addr.2003.12.002 ↗
35. Polymer conjugates as anticancer nanomedicines10.1038/nrc1958 ↗
36. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy10.1016/j.nantod.2010.05.001 ↗
37. Polymers in drug delivery—State of the art and future trends10.1002/adem.201080088 ↗
38. ‘Stealth’corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption10.1016/S0927-7765(99)00156-3 ↗
39. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin10.1016/j.nano.2009.02.002 ↗
40. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs10.1016/S0928-0987(00)00114-7 ↗
41. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model10.1016/j.ijpharm.2010.10.015 ↗
42. Yuan, J.D., ZhuGe, D.L., Tong, M.Q., Lin, M.T., Xu, X.F., Tang, X., Zhao, Y.Z., and Xu, H.L. (2018). pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer. Artif. Cells Nanomed. Biotechnol., 1–12.10.1080/21691401.2017.1423495 ↗
43. Oxygen-generating hybrid polymeric nanoparticles with encapsulated doxorubicin and chlorin e6 for trimodal imaging-guided combined chemo-photodynamic therapy10.7150/thno.22989 ↗
44. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles10.1186/s13065-018-0434-1 ↗
45. Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells10.1016/j.ijpharm.2017.03.049 ↗
46. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles10.1016/S0142-9612(99)00125-8 ↗
47. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects10.5414/NPP28153 ↗
48. Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation10.1016/j.ijpharm.2016.11.047 ↗
49. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes10.2147/IJN.S161426 ↗
50. Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery10.1016/j.biomaterials.2011.07.004 ↗
51. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly (lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles10.1007/s11095-018-2404-7 ↗
52. Drug Targeting and Tumor Heterogeneity10.1016/j.jconrel.2008.09.074 ↗
53. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery10.1016/j.jconrel.2010.08.027 ↗
54. Tumor delivery of macromolecular drugs based on the EPR effect10.1016/j.addr.2010.03.011 ↗
55. Modulation of the tumor microenvironment for cancer treatment: A biomaterials approach10.3390/jfb6010081 ↗
56. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
57. Targeted nanoparticles encapsulating (−)-epigallocatechin-3-gallate for prostate cancer prevention and therapy10.1038/srep41573 ↗
58. Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer10.3389/fphar.2018.00125 ↗
59. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy10.3390/vaccines3030662 ↗
60. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy10.1016/j.biomaterials.2018.02.034 ↗
61. Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach10.1021/mp100153r ↗
62. Polchi, A., Magini, A., Mazuryk, J., Tancini, B., Gapiński, J., Patkowski, A., Giovagnoli, S., and Emiliani, C. (2016). Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: Formulation and in vitro characterization. Nanomaterials, 6.10.3390/nano6050087 ↗
63. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases10.1080/17425247.2016.1178237 ↗
64. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles10.1007/s12272-001-1191-8 ↗
65. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs10.1016/j.biomaterials.2008.08.004 ↗
66. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood–brain barrier10.2217/nnm.10.131 ↗
67. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers10.3109/1061186X.2011.589435 ↗
68. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-12310.1016/j.jconrel.2007.05.022 ↗
69. Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution10.1016/j.nano.2009.02.005 ↗
70. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice10.1016/j.biomaterials.2013.09.063 ↗
71. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: In vitro and in vivo characterization10.1186/s12951-018-0356-z ↗
72. Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease10.1080/10717544.2017.1359862 ↗
73. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases10.1080/15548627.2015.1136769 ↗
74. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates10.1016/j.ijpharm.2017.05.015 ↗
75. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice10.18632/oncotarget.20944 ↗
76. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease10.1016/j.colsurfb.2016.08.052 ↗
77. Rosmarinic acid- and curcumin-loaded polyacrylamide-cardiolipin-poly(lactide-co-glycolide) nanoparticles with conjugated 83-14 monoclonal antibody to protect β-amyloid-insulted neurons10.1016/j.msec.2018.05.062 ↗
78. Targeted delivery of rosmarinic acid across the blood-brain barrier for neuronal rescue using polyacrylamide-chitosan-poly(lactide-co-glycolide) nanoparticles with surface cross-reacting material 197 and apolipoprotein E10.1016/j.ijpharm.2017.05.039 ↗
79. Role of nanotechnology for enzyme replacement therapy in lysosomal diseases. A focus on Gaucher’s disease10.2174/0929867323666160210130608 ↗
80. Recent developments in therapeutic approaches for lysosomal storage diseases10.2174/157488911794079127 ↗
81. Absence of metabolic cross-correction in Tay-Sachs cells: Implications for gene therapy10.1074/jbc.M106164200 ↗
82. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay–Sachs disease10.1093/hmg/ddi216 ↗
83. Bicistronic lentiviral vector corrects β-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts10.1016/j.nbd.2005.04.017 ↗
84. Widespread distribution of β-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol10.1038/sj.gt.3302081 ↗
85. Hematopoietic Stem cell transplantation and lentiviral vector-based gene therapy for Krabbe’s disease: Present convictions and future prospects10.1002/jnr.23847 ↗
86. Hematopoietic stem cell gene therapy for storage disease: Current and new indications10.1016/j.ymthe.2017.03.025 ↗
87. Enzyme replacement therapy for lysosomal storage diseases
88. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders10.1007/s13346-012-0072-4 ↗
89. New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders10.1002/wnan.73 ↗
90. Monoolein-based nanoparticles for drug delivery to the central nervous system: A platform for lysosomal storage disorder treatment10.1016/j.ejpb.2018.10.005 ↗
91. Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M.A., Forni, F., and Scarpa, M. (2016). Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE, 11.10.1371/journal.pone.0156452 ↗
92. Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A10.1016/j.jconrel.2017.02.016 ↗
93. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA10.1038/nmat2444 ↗
94. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy10.1016/j.vaccine.2009.03.034 ↗
95. Nanosystems for simultaneous imaging and drug delivery to T cells10.1208/aapsj0902019 ↗
96. Nano based drug delivery systems: Recent developments and future prospects10.1186/s12951-018-0392-8 ↗
97. Development of nanoparticles for clinical use10.2217/nnm.14.81 ↗
98. Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases10.1016/j.nano.2014.12.014 ↗